Menarini Stemline at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Menarini Stemline exhibits at Booth 229 at ASH 2026 in New Orleans. Menarini Stemline supports a symposium on blastic plasmacytoid dendritic cell neoplasm. It pairs updated diagnostic pathways with current and emerging therapies aimed at CD123.
| Organization | ASH 2026 Attendance |
|---|---|
Menarini Stemline New York, NY | |
Menarini Group subsidiary developing and selling oncology drugs, including a CD123-directed therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN). | Booth Exhibiting at Booth 229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. |
Find decision makers at Menarini Stemline
Tell us what you sell and we’ll find the people at Menarini Stemline most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction